Provider Resources

Find information on opioid prescribing, naloxone co-prescribing, and the Idaho Prescription Drug Monitoring Program below. 

Idaho Prescription Drug Monitoring Program (PDMP)

The Idaho PDMP is a statewide electronic database that collects designated data on controlled substances dispensed in Idaho. The Idaho PDMP is connected with PDMPs in neighboring states. This tool is for prescribers of controlled substances and pharmacists who are considering dispensing controlled substance prescriptions to patients.

The Idaho PDMP serves several purposes:

  • Supports access to legitimate medical use of controlled substances
  • Identifies and deters or prevents drug abuse and diversion
  • Helps identify and facilitates treatment of person with opioid use disorder (or substance use disorder)
  • Avoids dangerous combinations of benzodiazepines and opioids
  • Informs public health initiatives through analysis of the PDMP database

Beginning October 1, 2020, Idaho providers are required to check the PDMP prior to issuing an opioid or benzodiazepine prescription that is for more than a 3-day supply.

 

PDMP Login
Click the link to login and register for the Idaho PDMP.

Opioid prescribing resources

Signs of opioid misuse

As a healthcare provider, you have a responsibility to ensure controlled substances are prescribed solely for a genuine medical need.

While there's no uniform way to identify medication misuse, there are some common signs you may see:

  • Assertive personality (e.g., demanding immediate action)
  • Unusual knowledge of controlled substances
  • Gives medical history with textbook answers or gives vague answers relating to their medical history
  • May request a specific drug and be reluctant to try something different
  • No interest in diagnosis and often fails to keep appointments for further diagnostic tests or consultation with another practitioner
  • Patient may decline permission to obtain past records                                                               
  • Claims to be a patient of a practitioner that is not currently available
  • Has multiple unexplained dose escalation or non-adherence to treatment plans
Naloxone co-prescribing

Naloxone co-prescribing is one important tool prescribers can use to help prevent opioid overdose deaths. Co-prescribing naloxone is strongly recommended for patients at-risk for opioid overdose. In continuing these efforts, prescribers and other healthcare providers can monitor patients for risk of overdose, prescribe or dispense naloxone when overdose risk factors are present, and teach patients on how to use it.

Idaho’s law allows pharmacists and other health professionals to prescribe and dispense to anyone at risk for an opioid-related overdose or to anyone who may encounter such an individual.

MME calculator
Calculating the total daily dose of opioids helps identify patients who are at higher risk of overdose. 

Use extra precautions for patients at ≥50 MME/day. Consider closely monitoring patients, reducing or tapering of opioids, and/or prescribing of naloxone. Avoid or carefully justify increasing dosage to ≥90 MME/day.

Calculating MME

1. Determine the total daily amount of each opioid the patient takes

2. Convert each to MME — multiply the dose for each opioid by the conversion factor (see table)

3. Add them together

Select the link to access a free opioid dose calculator 

Tapering dosages

Clinicians should carefully weigh both the benefits and risks of continuing opioid medications and the benefits and risks of tapering opioids. The 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain does not support rapid dosage tapering, patient abandonment, or abrupt discontinuation of opioids. 

General considerations for changing opioid dosages:

  • If benefits outweigh risks of continued opioid therapy, clinicians should work closely with patients to optimize nonopioid therapies while continuing opioid therapy.
  • When benefits (including avoiding risks of tapering) do not outweigh risks of continued opioid therapy, clinicians should optimize other therapies and work closely with patients to gradually taper to a reduced opioid dosage or, if warranted based on the individual clinical circumstances of the patient, appropriately taper and discontinue opioid therapy.

For more guidance on tapering opioid prescriptions, refer to the Summary of the 2022 Clinical Practice Guideline for Prescribing Opioids for Pain